IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v8y2010i5p327-341.html
   My bibliography  Save this article

Cost effectiveness of long-acting risperidone in Sweden

Author

Listed:
  • Marja Hensen
  • Bart Heeg
  • Mickael Löthgren
  • Ben Hout

Abstract

Treatment with RLAI is suggested to result in improved QALYs combined with cost savings compared with haloperidol LAI among the Swedish, high-risk non-compliant schizophrenia patient population. In the general schizophrenia population, RLAI also resulted in positive incremental QALYs and cost savings, when compared with olanzapine. However, the estimates used in the model for compliance and symptom reduction need further validation through naturalistic-based studies with reasonable follow-up to more definitely establish the real-life differences between RLAI and the comparators in the considered patient populations and to further reduce the uncertainty of these parameters. Copyright Adis Data Information BV 2010

Suggested Citation

  • Marja Hensen & Bart Heeg & Mickael Löthgren & Ben Hout, 2010. "Cost effectiveness of long-acting risperidone in Sweden," Applied Health Economics and Health Policy, Springer, vol. 8(5), pages 327-341, September.
    • Handle: RePEc:spr:aphecp:v:8:y:2010:i:5:p:327-341
    DOI: 10.2165/11536180-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11536180-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/11536180-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Gisela Paula González & Nebel Silvana Moscoso & Fernando Pablo Lago, 2018. "A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina," PharmacoEconomics - Open, Springer, vol. 2(3), pages 233-239, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:8:y:2010:i:5:p:327-341. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.